Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Heading to RSNA 2024? Us2.ai ? Ascend Cardiovascular ?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by jopatcloon Dec 01, 2024 12:17pm
36 Views
Post# 36339609

RE:RE:RE:Heading to RSNA 2024? Us2.ai ? Ascend Cardiovascular ?

RE:RE:RE:Heading to RSNA 2024? Us2.ai ? Ascend Cardiovascular ?Sorry, still a bit complicated to copy the translation
Remember Pandora FDA 510K submission under review.& See the (@facts rule Your amigos GranhamB the vulture on ceo)
Ventripoint creates sales program for US expansion 2024-11-19 17:42
& -Press release Mr. Hugh MacNaught reports In the United States, VMS+ has been acquired by: *Duke University Hospital; *Mayo Clinic; *Phoenix Children's Hospital; *Seattle Children's Hospital.
& see #1 Mayo Clinic cardiac center in the entire world.
https://www.newsweek.com/rankings/worlds-best-specialized-hospitals-2024/cardiology
Remember  24-11-2023 low = 0.135 & 08-01-2024 high = 0.36  
 
 
Reposting: Ventripoint's VMS+4.0: Health Canada License issued in August, MDR application accepted for Europe CE mark last month, FDA 510K submission under review. Working in the medical device regulated industry isn't for the faint hearted. I used to think working in aviation and aerospace, regulated by the FAA, CAA, EASA was tough. If anything it prepared me for the medical device space! Ventripoint Diagnostics Ltd. MedicalDeviceAI CardiacEcho

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities